

AGENDA Spring Meeting 2016

08 – 09 April 2016

Courtyard by Marriott Madrid Princesa Hotel
Madrid, Spain
Room: Rosales I

Friday 08 April 2015		
Time slot	Topic / Title of presentation	Moderator
8.30 – 10.00	Young investigators meeting	N. Ottevanger (Nijmegen, the Netherlands) A. Casado (Madrid, Spain)
10.00 – 10.15	Coffee break	
10.15 – 11.00	Ovarian Tumor Site Committee (including new ideas)	N. Ottevanger (Nijmegen, the Netherlands)
11.00 – 11.45	Endometrial Tumor Site Committee (including new ideas)	A. Casado (Madrid, Spain)
11.45 – 12.30	Cervix Tumor Site Committee (including new ideas)	G. Kenter (Amsterdam, the Netherlands)
12.30 – 13.30	Lunch	
13.30 – 20.00	<p>Scientific program</p> <p><i>“Recent advances in gynecological cancers. Clinicians and researchers at the cutting edge of molecular biology and clinical understanding of gynecological cancers”</i></p> <p>Chairs: A. Casado (Madrid, Spain) and N. Ottevanger (Nijmegen, The Netherlands)</p>	
13.30 – 13.45	Welcome and introduction	E. Díaz-Rubio (TBC) A. Casado (Madrid, Spain)
13.45 – 15.00	<p>Session I. Opportunities for translational research and its impact on the design of the new wave of clinical trials.</p> <ul style="list-style-type: none"> EUTROC (European Network Translational Research Ovarian Cancer) perspective. Hani Gabra (UK) (20 minutes) ENITEC perspective (European Network Individualized Treatment in Endometrial Cancer). Hannie Pijnenborg (Netherlands) (20 minutes) EORTC SPECTArare cancers. Ajlan Atasoy. EORTC HQ. Brussels (20 minutes) Discussion (15 minutes) 	Deolindas Pereira or Susana de Sousa (TBC) Anita Wolfer (Lausanne, Switzerland)
15.00 – 15.50	<p>Session 2. Ovarian cancer (part 1)</p> <ul style="list-style-type: none"> Molecular biology and new insights in anti-angiogenic therapy in ovarian cancer. What we know about anti-angiogenesis and what we should know. Ian McNeish (UK) (20 minutes) 	Marga Romeo (Barcelona, Spain) Margaret Hutka (London, UK)

AGENDA Spring Meeting 2016

08 – 09 April 2016

Courtyard by Marriott Madrid Princesa Hotel
Madrid, Spain
Room: Rosales I

	<ul style="list-style-type: none"> PARP-i inhibitors in recurrent ovarian cancer. What we know and what we would like to know. Susana Banerjee (UK) (20 minutes) Discussion (10 minutes) 	
15.50 – 16.00	<i>Coffee break</i>	
16.00 – 17.50	<p>Session 2. Ovarian cancer (part 2)</p> <ul style="list-style-type: none"> Rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment in ovarian cancer. Molecular characterization of ovarian cancer. Ignace Vergote (Leuven, Belgium) (20 minutes) Overcoming platinum-resistance in recurrent disease. Potential role of trabectedin. Nicoletta Colombo (Milano, Italy) (20 minutes) Discussion: 10 minutes 	<p>Marga Romeo (Barcelona, Spain) Margaret Hutka (London, UK)</p>
17.50 – 18.40	<p>Session 3. Immunotherapy</p> <ul style="list-style-type: none"> Present and future of immunotherapy strategies in gynecological cancers. Ovarian cancer. Lana Kandalaft (Lausanne, Switzerland) (20 minutes) Immunotherapy approaches to endometrial and cervix cancer. Anita Wolfer (Lausanne, Switzerland) (20 minutes) Discussion (10 minutes) 	<p>Emad Shash (National Cancer Institute, Cairo) Stanley Hato (Radboud University, Nijmegen, The Netherlands)</p>
18.40 – 19.30	<p>Session 4. Endometrial and cervix cancer.</p> <ul style="list-style-type: none"> Endometrial cancer. New insights in molecular biology and the future wave of clinical trials (20 minutes). Nick Reed (Glasgow, UK) Cervix cancer, angiogenesis and immunotherapy. Key challenging issues to be addressed next. (20 minutes). Antonio Casado Discussion (10 minutes) 	<p>Fernanda Herrera (Lausanne, CH) A. Oaknin (Barcelona, Spain)</p>
19.30 – 20.00	<p>Special session. Current and future role of patient advocacy groups in gynecological cancer research (John Green, Liverpool, UK) (20 minutes)</p>	<p>A. Casado (Madrid, Spain)</p>
20.45 -	<i>Dinner</i>	

AGENDA Spring Meeting 2016

08 – 09 April 2016

Courtyard by Marriott Madrid Princesa Hotel
Madrid, Spain
Room: Rosales I

Saturday 09 April 2016		
Time slot	Topic / Title of presentation	Moderator
8.30 – 10.00	General Assembly and Business meeting	N. Ottevanger (Nijmegen, The Netherlands)
10.00 – 10.30	Translational Research Subcommittee	S. Scholl (Paris, France)
<i>10.30 – 10.45</i>	<i>Coffee break</i>	
10.45 – 11.30	ROG/GCG working party	F. Herrera (Lausanne, Switzerland)
11.30 – 12.00	Survivorships and quality of life issues <ul style="list-style-type: none"> • Update on the EORTC follow-up project. E. Greimel (Graz, Austria) (15 minutes) • The relevance of patient reported outcomes (PROs) in the molecular and personalized medicine era. Key issues for the next generation of clinical trials. E. Greimel (Graz, Austria) (15 minutes) • Incorporating Patient Reported Outcomes in GCIG Ovarian Cancer Trials. Challenges and Opportunities. N. Ottevanger (Nijmegen, The Netherlands) (15 minutes) 	E. Greimel (Graz, Austria) A. Nordin (Margate, UK) E. van Dorst (Utrecht, The Netherlands)
<i>12.00 – 13.00</i>	<i>Lunch</i>	
13.00 – 13.30	Quality Assurance Subcommittee	A. Ferrero (Torino, Italy)
13.30 – 14.00	Chemotherapy Subcommittee	I. Boere (Rotterdam, The Netherlands)
14.00 – 14.30	Surgical Subcommittee	E. van Dorst (Utrecht, The Netherlands)
14.30 – 15.00	Closure of the meeting Fall GCG meeting Lausanne, Switzerland 23-24 September 2016 Local organizers: G. Coukos, F. Herrera, A. Wolfer	